Doesn't GDC-0084 already beat the control (temozolomide) on toxicity? Perhaps agile is purely focused on survival and or progression free - if so the competition may well be doing better under that scenario up to this point but toxicity would be a factor in many situations where the patients cannot tolerate the regime. Only time can reveal a lot of this it can't be be rushed though I get the thinking with agile given there is next to nothing currently - the whole thing is experimental. JG & Co joined an experimental trial system (agile) with an experimental drug - none may make it through to the end...
KZA Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
